Abstract | BACKGROUND: METHODS: This investigator-initiated and -driven, multicenter, open-label, randomized, controlled trial (UMIN000020868) enrolled 39 patients with predicted SAP and low enhancement of the pancreatic parenchyma on computed tomography (CT). Twenty patients were assigned to the CRAI group, while 19 served as controls and were administered NM at the same dose intravenously (IV group). The primary endpoint was the development of pancreatic necrosis as determined by CT on Day 14, judged by blinded central review. RESULTS: There was no difference between the CRAI and IV groups regarding the percentages of participants who developed pancreatic necrosis (more than 1/3 of the pancreas: 25.0%, range 8.7-49.1% vs. 15.8%, range 3.4-39.6%, respectively, P = 0.694; more than 2/3 of the pancreas: 20%, range 5.7-43.7% vs. 5.3%, range 0.1-26.0%, respectively, P = 0.341). The early analgesic effect was evaluated based on 24-h cumulative fentanyl consumption and additional administration by intravenous patient-controlled analgesia. The results showed that the CRAI group used significantly less analgesic. There were two adverse events related to CRAI, namely bleeding and splenic infarction. CONCLUSIONS: CRAI with NM did not inhibit the development of pancreatic necrosis although early analgesic effect of CRAI was superior to that of IV. Less-invasive IV therapy can be considered a viable alternative to CRAI therapy.
|
Authors | Morihisa Hirota, Tooru Shimosegawa, Katsuya Kitamura, Kazunori Takeda, Yoshifumi Takeyama, Toshihiko Mayumi, Tetsuhide Ito, Mamoru Takenaka, Eisuke Iwasaki, Hirotaka Sawano, Etsuji Ishida, Shin Miura, Atsushi Masamune, Yousuke Nakai, Akira Mitoro, Hiroyuki Maguchi, Kenji Kimura, Tsuyoshi Sanuki, Tetsuya Ito, Hiroki Haradome, Kazuto Kozaka, Toshifumi Gabata, Keisho Kataoka, Masahiko Hirota, Shuji Isaji, Ryoji Nakamura, Koki Yamagiwa, Chie Kayaba, Koji Ikeda |
Journal | Journal of gastroenterology
(J Gastroenterol)
Vol. 55
Issue 3
Pg. 342-352
(Mar 2020)
ISSN: 1435-5922 [Electronic] Japan |
PMID | 31758329
(Publication Type: Clinical Trial, Phase II, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Benzamidines
- Guanidines
- Protease Inhibitors
- nafamostat
|
Topics |
- Administration, Intravenous
- Adult
- Aged
- Benzamidines
(administration & dosage, adverse effects)
- Female
- Guanidines
(administration & dosage, adverse effects)
- Humans
- Infusions, Intra-Arterial
- Japan
- Male
- Middle Aged
- Pancreatitis
(complications, drug therapy)
- Pancreatitis, Acute Necrotizing
(diagnostic imaging, prevention & control)
- Protease Inhibitors
(administration & dosage, adverse effects)
- Severity of Illness Index
- Tomography, X-Ray Computed
- Treatment Outcome
- Young Adult
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|